Drug Profile

RECCE 529

Alternative Names: R 529; RECCE-529

Latest Information Update: 16 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Recce Pharmaceuticals
Developer Path BioAnalytics; Recce Pharmaceuticals
Class Anti-infectives; Antivirals; Polymers
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical COVID 2019 infections

Most Recent Events

27 Feb 2025 Recce Pharmaceuticals has patent protection for RECCE® 327 and RECCE® 529 in Japan
30 Jan 2025 RECCE 529 is still in preclinical development in COVID-2019-infections (Prevention) in Australia (Parenteral) (Recce Pharmaceuticals pipeline, January 2025)
28 Dec 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in Australia (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com